Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of salvianolic acid A in preparation of drugs for preventing and/or treating pulmonary arterial hypertension

A technology of pulmonary arterial hypertension and salvianolic acid, which is applied in the field of preparation of products for preventing, alleviating and/or treating pulmonary arterial hypertension and its complications, can solve problems such as not finding pulmonary arterial hypertension, and achieve relief of pulmonary arteriolar remodeling and improvement of enlargement Symptoms, the effect of improving right ventricular hypertrophy

Inactive Publication Date: 2016-12-07
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, we have not found any relevant reports on the treatment of pulmonary arterial hypertension with salvianolic acid A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid A in preparation of drugs for preventing and/or treating pulmonary arterial hypertension
  • Application of salvianolic acid A in preparation of drugs for preventing and/or treating pulmonary arterial hypertension
  • Application of salvianolic acid A in preparation of drugs for preventing and/or treating pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1: the establishment of pulmonary arterial hypertension rat model

[0029] Wild lily is an alkaloid extracted from the leguminous plant Lilium wild. Monocrotaline itself is inactive. After entering the body, it is absorbed into the liver through the portal vein, and after liver metabolism, it forms a dehydrogenated product, pyrrocrotaline, which circulates to the pulmonary artery and damages the endothelial cells of the pulmonary artery, causing its degeneration, necrosis, shedding, and in situ thrombosis. , causing thickening of the media of the pulmonary arterioles, eventually leading to pulmonary arteriolar remodeling and increased pulmonary artery pressure. The present embodiment adopts the animal model of rat pulmonary hypertension caused by subcutaneous injection of monocrotaline, observes and records the electrocardiogram of rats, measures rat visceral index, hemodynamic index, measures rat serum marker enzymes and histomorphological changes, Determin...

Embodiment 2

[0033] Example 2: The improvement effect of salvianolic acid A on electrocardiogram in rats with pulmonary arterial hypertension.

[0034] After the last administration, the rats in the above groups were anesthetized with 0.2ml / kg of 10% chloral hydrate, needle-shaped electrodes were inserted subcutaneously in the front and rear limbs, and the electrocardiogram was recorded in lead II of the limbs to observe the changes of S waves. The results show (attached figure 1 ), the electrocardiogram of normal rats was normal, but in the model group, due to the compensatory hypertrophy of the right ventricle and the enlargement of the right ventricle cavity, the S wave was deepened, and the T wave inversion could appear in severe cases. The positive drug bosentan can significantly improve the ECG changes caused by pulmonary hypertension, and salvianolic acid A can improve the above-mentioned pathological ECG changes in a dose-dependent manner, indicating that salvianolic acid A has a g...

Embodiment 3

[0035] Example 3: Effect of salvianolic acid A on hemodynamic indexes in rats with pulmonary arterial hypertension

[0036] After the electrocardiogram observation, the left common carotid artery of the rats was bluntly separated, and a pressure transducer was connected through a PE50 catheter. After the recording, the common carotid artery on the side was ligated. The right external jugular vein was bluntly dissected, and the pressure of the right ventricle of the rats was detected by classical right heart catheterization. The average systolic blood pressure of each group was recorded and counted. Systemic circulation results display (attached figure 2 ), there were no significant differences in heart rate, systolic and diastolic blood pressure among the groups. It shows that the drug has no obvious effect on the systemic circulation. The results of right ventricular pressure were significant (attached figure 2 ) showed that the right ventricular pressure in the model g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and / or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

Description

technical field [0001] The invention relates to the novel pharmacological action of salvianolic acid A, a monomer component of traditional Chinese medicine, and the use of salvianolic acid A in the preparation of products for preventing, alleviating and / or treating pulmonary hypertension and its complications, belonging to the technical field of traditional Chinese medicine. technical background [0002] Pulmonary hypertension is a very serious disease. 75% of patients are concentrated in the age group of 20 to 40 years old, and 15% of patients are under 20 years old. Right heart catheterization is the gold standard for the diagnosis of pulmonary arterial hypertension. Hemodynamic indicators can predict the survival time of patients with pulmonary arterial hypertension. At sea level, pulmonary artery systolic pressure > 30mmHg (1mmHg = 0.133kPa) in resting state, mean pulmonary artery pressure > 25mmHg, or mean pulmonary artery pressure > 30mmHg in active state ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P9/12A61P11/00A61P9/00A61P9/04A23L33/10
CPCA61K31/216A23V2002/00A23V2200/314A23V2200/326A23V2250/2132
Inventor 方莲花杜冠华陈俞材袁天翊徐晓娜牛子冉
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com